iBio Inc (IBIO)
1.95
+0.02
(+1.04%)
USD |
NYAM |
Apr 16, 15:31
iBio Enterprise Value: 16.59M for April 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 15, 2024 | 16.59M |
| April 12, 2024 | 16.91M |
| April 11, 2024 | 16.80M |
| April 10, 2024 | 16.91M |
| April 09, 2024 | 17.43M |
| April 08, 2024 | 17.74M |
| April 05, 2024 | 17.22M |
| April 04, 2024 | 18.54M |
| April 03, 2024 | 20.11M |
| April 02, 2024 | 19.83M |
| April 01, 2024 | 21.54M |
| March 28, 2024 | 24.01M |
| March 27, 2024 | 21.57M |
| March 26, 2024 | 13.87M |
| March 25, 2024 | 13.68M |
| March 22, 2024 | 13.66M |
| March 21, 2024 | 13.63M |
| March 20, 2024 | 13.60M |
| March 19, 2024 | 13.56M |
| March 18, 2024 | 13.53M |
| March 15, 2024 | 13.53M |
| March 14, 2024 | 13.84M |
| March 13, 2024 | 13.91M |
| March 12, 2024 | 13.91M |
| March 11, 2024 | 13.98M |
| Date | Value |
|---|---|
| March 08, 2024 | 13.98M |
| March 07, 2024 | 13.98M |
| March 06, 2024 | 14.05M |
| March 05, 2024 | 14.12M |
| March 04, 2024 | 14.22M |
| March 01, 2024 | 14.19M |
| February 29, 2024 | 14.26M |
| February 28, 2024 | 14.08M |
| February 27, 2024 | 13.94M |
| February 26, 2024 | 14.01M |
| February 23, 2024 | 14.05M |
| February 22, 2024 | 14.05M |
| February 21, 2024 | 13.98M |
| February 20, 2024 | 14.26M |
| February 16, 2024 | 14.26M |
| February 15, 2024 | 14.12M |
| February 14, 2024 | 14.08M |
| February 13, 2024 | 14.12M |
| February 12, 2024 | 14.08M |
| February 09, 2024 | 13.98M |
| February 08, 2024 | 13.86M |
| February 07, 2024 | 13.42M |
| February 06, 2024 | 13.44M |
| February 05, 2024 | 13.44M |
| February 02, 2024 | 13.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.373M
Minimum
Nov 27 2019
843.20M
Maximum
Jul 20 2020
92.65M
Average
34.97M
Median
Jun 28 2022
Enterprise Value Benchmarks
| Lixte Biotechnology Holdings Inc | 6.719M |
| PAVmed Inc | 75.16M |
| Avalo Therapeutics Inc | 8.066M |
| Imunon Inc | -1.878M |
| Ocugen Inc | 354.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.211M |
| Total Expenses (Quarterly) | 4.496M |
| EPS Diluted (Quarterly) | -4.42 |
| Earnings Yield | -770.3% |
| Normalized Earnings Yield | -1894.36 |